von Arx, C.; Rea, G.; Napolitano, M.; Ottaiano, A.; Tatangelo, F.; Izzo, F.; Petrillo, A.; Clemente, O.; Di Sarno, A.; Botti, G.;
et al. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. Cancers 2020, 12, 2422.
https://doi.org/10.3390/cancers12092422
AMA Style
von Arx C, Rea G, Napolitano M, Ottaiano A, Tatangelo F, Izzo F, Petrillo A, Clemente O, Di Sarno A, Botti G,
et al. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. Cancers. 2020; 12(9):2422.
https://doi.org/10.3390/cancers12092422
Chicago/Turabian Style
von Arx, Claudia, Giuseppina Rea, Maria Napolitano, Alessandro Ottaiano, Fabiana Tatangelo, Francesco Izzo, Antonella Petrillo, Ottavia Clemente, Antonella Di Sarno, Gerardo Botti,
and et al. 2020. "Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study" Cancers 12, no. 9: 2422.
https://doi.org/10.3390/cancers12092422
APA Style
von Arx, C., Rea, G., Napolitano, M., Ottaiano, A., Tatangelo, F., Izzo, F., Petrillo, A., Clemente, O., Di Sarno, A., Botti, G., Scala, S., & Tafuto, S., on behalf of the ENETs Center of Excellence of Naples, Italy.
(2020). Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. Cancers, 12(9), 2422.
https://doi.org/10.3390/cancers12092422
